NEW ORLEANS — Merck says sotatercept, Acceleron’s lead drug before the Big Pharma bought it for $11.5 billion, significantly improved scores on an exercise test in a pivotal trial for pulmonary arterial hypertension (PAH). Now, Merck is working toward an FDA …